Company profile: Variant Bio
1.1 - Company Overview
Company description
- Provider of genomics-driven drug discovery, using whole-genome sequencing and custom algorithms to identify novel, population-specific variants and disease-relevant targets. Offers research partnerships, benefit-sharing programs, and an Affordable Medicines Pledge, plus the Variant Bio Standley Fellowship for genomic data analysis and partnerships with populations with specific health-related traits.
Products and services
- Research Partnerships: Variant Bio collaborates with communities, academics, and healthcare professionals to conduct genetic studies on unique health traits (worldwide)
- Genomic Discovery: Variant Bio employs whole-genome sequencing and custom algorithms to pinpoint novel and population-specific genetic variants for drug discovery (custom-algorithmic)
- Research & Development: Variant Bio focuses on identifying disease-relevant phenotypes and targets with strong human genetics for drug discovery (human-genetics–anchored)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Variant Bio
Invitae
HQ: United States
Website
- Description: Provider of medical genetics services delivering comprehensive genetic information to guide healthcare decisions. Offers genetic testing for diseases and medical conditions; genetic counseling at no additional cost in specified regions; a Billing Assurance Program for cost-effective payment options; Invitae Generation using advanced machine learning for testing and classification; proactive health tests focusing on cancer and cardiovascular conditions; and sponsored no-charge testing via biopharma partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Invitae company profile →
Envisagenics
HQ: United States
Website
- Description: Provider of AI/ML-driven RNA sequencing analysis solutions to accelerate therapeutic development. Offers SpliceCore, a platform that analyzes RNA splicing events to discover drug targets, and SpliceIO, a machine learning module that identifies RNA splicing-derived neoepitopes for immunotherapy, reducing biomedical data complexity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envisagenics company profile →
Agritope
HQ: United States
Website
- Description: Provider of new fruit and vegetable plant varieties for the fresh produce industry, utilizing patented ethylene control technology to develop fruits and vegetables resistant to the decaying effects of ethylene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agritope company profile →
LogicBio Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy vectors for previously incurable genetic and infectious diseases, committed to delivering genetic medicine to pediatric patients with rare diseases. Utilizes proprietary technology based on a non-pathogenic adeno-associated viral vector, offering superior efficiency and safety compared to competitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LogicBio Therapeutics company profile →
AccuraGen
HQ: United States
Website
- Description: Provider of cancer early detection solutions: a liquid biopsy platform using unique biochemistry and machine learning to extract cancer signals in plasma for treatment guidance, minimal residue disease detection, and early screening; and CLAmp-seq technology to detect multiple cancer signals in blood and analyze them with machine learning for multi-cancer early detection tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AccuraGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Variant Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Variant Bio
2.2 - Growth funds investing in similar companies to Variant Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Variant Bio
4.2 - Public trading comparable groups for Variant Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →